Workflow
Aclaris Therapeutics(ACRS) - 2025 Q1 - Quarterly Results
ACRSAclaris Therapeutics(ACRS)2025-05-08 11:15

Financial Performance - Aclaris reported a net loss of 15.1millionforQ12025,adecreasefromanetlossof15.1 million for Q1 2025, a decrease from a net loss of 16.9 million in Q1 2024[14] - Total revenue for Q1 2025 was 1.5million,downfrom1.5 million, down from 2.4 million in Q1 2024, primarily due to reduced royalty payments[14] - Net loss for Q1 2025 was 15,085,000,animprovementfromanetlossof15,085,000, an improvement from a net loss of 16,941,000 in Q1 2024[26] - Depreciation and amortization expenses decreased to 128,000from128,000 from 243,000 year-over-year[26] - Stock-based compensation expense increased to 3,535,000comparedto3,535,000 compared to 2,089,000 in the previous year[26] - Revaluation of contingent consideration was 300,000,downfrom300,000, down from 2,800,000 in the prior year[26] - Changes in operating assets and liabilities resulted in a cash outflow of 1,935,000,animprovementfrom1,935,000, an improvement from 9,006,000 in Q1 2024[26] - Net cash used in operating activities was 13,057,000,comparedto13,057,000, compared to 20,815,000 in the same quarter last year[26] Cash Position and Runway - Aclaris ended Q1 2025 with 190.5millionincash,cashequivalents,andmarketablesecurities,downfrom190.5 million in cash, cash equivalents, and marketable securities, down from 203.9 million at the end of 2024[13] - The expected cash runway has been extended through the first half of 2028, fully funding preclinical and clinical development plans[9] Research and Development - Research and development expenses increased to 11.6millioninQ12025from11.6 million in Q1 2025 from 9.8 million in the prior year, driven by costs associated with the bosakitug program[15] - Aclaris plans to initiate a Phase 2 trial for bosakitug in atopic dermatitis with approximately 90 patients in Q2 2025[3] - Top line results from the Phase 2a trial of ATI-2138 in atopic dermatitis are expected in June 2025[6] - The IND application for ATI-052 was cleared by the FDA, with plans to initiate a Phase 1 trial in Q2 2025[7] - Aclaris is exploring partnerships for the global development of bosakitug in respiratory indications[10] - The company aims to develop next-generation ITK inhibitors and bispecific antibodies targeting cytokine pathways, with new IND submissions expected starting in 2026[11]